Chin J Traumatol. 2026 Aug 17:S1008-1275(26)00149-5. doi: 10.1016/j.cjtee.2026.06.003. Online ahead of print.
ABSTRACT
PURPOSE: To investigate the current status of monoclonal anti-tetanus toxin antibody used for passive immunization in the prevention and management of post-traumatic tetanus in China, and to provide evidence for the selection of passive immunization agents for tetanus prophylaxis.
METHODS: This retrospective, multicenter, real-world survey included patients who received a monoclonal anti-tetanus toxin antibody (siltartoxatug injection) for passive immunization following traumatic injury at participating hospitals across China between March 1 and August 20, 2025. Patients with incomplete registration data or at least 1 missing key variable were excluded. Demographic, clinical, wound-related, payment, and follow-up information was collected. According to the National Clinical Practice Guideline for Non-neonatal Tetanus Prevention and Treatment (2024 Edition), patients were classified into high- and low-risk tetanus exposure groups based on vaccination history, booster interval, wound characteristics, and immune status. Demographic, clinical, and wound-related characteristics were compared between the 2 groups. Statistical analyses were performed using IBM SPSS Statistics, version 26.0 (IBM Corp., Armonk, NY, USA). Categorical variables were presented as frequencies and percentages and compared using the chi-square test or Fisher’s exact test, as appropriate. All statistical tests were two-sided, and a p value < 0.05 was considered statistically significant.
RESULTS: A total of 423 hospitals from 28 provinces, autonomous regions, and municipalities participated in the survey and provided case data. Among 1474 patients who received monoclonal anti-tetanus toxin antibody for passive immunization following trauma, no tetanus cases were documented during the available observation period; however, follow-up duration was not standardized across centers, and the protective efficacy of the monoclonal antibody could not be definitively evaluated.
CONCLUSION: Standardized wound assessment and appropriate selection of passive immunization agents are crucial for tetanus prevention. Monoclonal anti-tetanus toxin antibody represents an effective and promising option for passive immunization against tetanus.
PMID:42608224 | DOI:10.1016/j.cjtee.2026.06.003
